ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 0420

Development and Validation of a Simulation Model for Maintenance Treatment in ANCA-Associated Vasculitis

Zachary Wallace1, John Stone2, Hyon K. Choi3 and Emily Hyle4, 1Massachusetts General Hospital, Newton, MA, 2Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, 3Massachusetts General Hospital, Lexington, MA, 4Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Boston, MA

Meeting: ACR Convergence 2021

Keywords: ANCA associated vasculitis, Simulation Model, Vasculitis

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 6, 2021

Session Title: Vasculitis – ANCA-Associated Poster (0414–0436)

Session Type: Poster Session A

Session Time: 8:30AM-10:30AM

Background/Purpose: ANCA-associated vasculitis (AAV) care has evolved over the last two decades with several approaches to remission maintenance. However, these approaches have trade-offs regarding the risk of flare, infection, end-stage renal disease (ESRD), and other outcomes which impact morbidity, mortality, and costs. We developed a simulation model to project clinical outcomes in individuals with specific disease features, which can be used to inform clinical decision-making and identify uncertainties that strongly affect outcomes.

Methods: We developed a state-transition, microsimulation model of people with AAV (TreeAge Pro Healthcare 2020). Figure 1 displays the health states; individuals remain in or transition between health states monthly. At model start, individuals draw for demographic and disease-specific characteristics and then transition between the active AAV or inactive states (i.e., relapse/remission, stratified by major/minor severity) and are at risk for severe infection, ESRD, or death. Transition rates are stratified by demographic and disease-specific characteristics. Table 1 shows model input parameters. The distribution of baseline demographics (i.e., age, sex, ANCA type, renal involvement) are from the MAINRITSAN 2 trial, which compared fixed-schedule rituximab (RTX) to a tailored approach based on rising ANCA or B cell titers for remission maintenance. We obtained probabilities of relapse, severe infection, and ESRD from MAINRITSAN 2, and other clinical trials, cohort studies, and national registries. We estimated mortality based on disease-specific features and background age- and sex-adjusted rates derived from US life tables. We then used the AAV model to project outcomes with tailored vs fixed-schedule RTX among people in remission at baseline over 28 months, as studied in MAINRITSAN 2. We performed face validity assessment with experts in the field. We used mean average percent error (MAPE) to assess how the model-projected outcomes compared to those observed in MAINRITSAN 2.

Results: Over 28 months, the AAV model projected fewer minor and major relapses with fixed vs tailored RTX (7.4% [95% CI 6.9%-7.9%] vs 10.1% [9.5%-10.7%] and 4.3% [3.9% vs 4.7%] vs 7.0% [6.5%-7.5%]). More patients had at least one severe infection in the fixed vs tailored group (19.1% [18.2%-20.0%] vs 10.9% [10.3%-11.6%]). ESRD was uncommon in both groups (0.5% [0.4%-0.6%] vs 0.6% [0.5%-0.8%]). The mean survival was the same in both strategies (27.0 ± 3.9 vs 27.0 ± 3.8 months). Compared to the MAINRITSAN 2 trials results (Table 2), the projected rates of relapse, severe infection, ESRD, and death in the AAV model were similar (MAPE, 1.5%, range 0.4%-4.3%). Limitations include that we made assumptions regarding differences in mortality rates during active vs inactive disease states.

Conclusion: We established the face validity and internal validation of a novel AAV state-transition model that projects key outcomes, including minor and major relapse, severe infection, ESRD, and death. This model can be adapted to compare other strategies (e.g., azathioprine) and incorporate other health states (e.g., steroid toxicity), quality of life, and costs.

Figure 1: AAV State-Transition Model

Table 1: Model Input Parameters

Table 2: Comparison of AAV Model Projected Outcomes with MAINRITSAN 2 Outcomes Over 28 Months


Disclosures: Z. Wallace, Bristol-Myers Squibb, 5, Principia/Sanofi, 5, Viela Bio, 2, MedPace, 2; J. Stone, Principia Biopharma Inc, a Sanofi Company, 5, 12, personal fees; H. Choi, None; E. Hyle, None.

To cite this abstract in AMA style:

Wallace Z, Stone J, Choi H, Hyle E. Development and Validation of a Simulation Model for Maintenance Treatment in ANCA-Associated Vasculitis [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/development-and-validation-of-a-simulation-model-for-maintenance-treatment-in-anca-associated-vasculitis/. Accessed February 3, 2023.
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/development-and-validation-of-a-simulation-model-for-maintenance-treatment-in-anca-associated-vasculitis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences